- •Corneal Disease
- •Preface
- •Contents
- •Contributors
- •Core Messages
- •Organisms
- •Detection
- •Acid Fast Smears
- •Culture Media
- •Molecular Tests
- •Nucleic Acid Hybridization Probes
- •Line Probes
- •DNA Sequencing
- •FISH (Fluorescent In Situ Hybridization) Assay
- •DNA Microarray
- •Pulse Field Gel Electrophoresis (PFGE)
- •Management
- •Clinical Diagnosis
- •Medical Therapy
- •Surgical Intervention
- •Penetrating Keratoplasty
- •Corneal Cross-Linking
- •Summary for the Clinician
- •References
- •Core Messages
- •Introduction
- •Epidemiology
- •Visual Morbidity
- •Documentation
- •Causative Factors
- •Causative Bacteria
- •Investigation of Keratitis
- •Laboratory Diagnosis: Susceptibility Testing
- •Susceptibility and Resistance of Bacterial Isolates
- •Treatment: Antimicrobials
- •Current Antimicrobials in Use
- •The Fluoroquinolones
- •Aminoglycosides
- •Cephalosporins
- •Other Antimicrobials Used
- •Development of Existing and New Classes of Drugs
- •Tigecycline
- •Linezolid
- •Meropenem
- •Combination Therapy
- •Drug Delivery to the Cornea
- •Novel Methods of Drug Delivery to the Cornea
- •Conclusion
- •References
- •3: Heredity of Keratoconus
- •Introduction
- •Is Keratoconus a Heritable or Genetic Disease?
- •Mutational Screening of Candidate Genes in Keratoconus
- •Visual System Homeobox Gene 1 (VSX1)
- •Superoxide Dismutase 1 (SOD1)
- •Interleukin 1 (IL1) Superfamily
- •Collagen Genes
- •Genetic Mapping in Keratoconus
- •Genetics of Keratoconus – Mendelian or Complex?
- •References
- •4: Advance in Corneal Imaging
- •Introduction
- •In Vivo Confocal Microscopy (IVCM)
- •Principles of Confocal Microscopy
- •The Normal Cornea
- •Clinical Applications
- •Infectious Keratitis
- •Corneal Dystrophies
- •Refractive Surgery
- •Corneal Surgery
- •Other Clinical Applications
- •Limitations of IVCM
- •Anterior Segment Ocular Coherence Tomography (OCT)
- •Clinical Applications
- •Corneal Thickness Assessment
- •Refractive Surgery
- •Corneal Grafts
- •Limitations
- •Conclusion
- •References
- •Core Messages
- •Introduction
- •“Angiogenic Privilege of the Cornea” or “How Does the Normal Corneal Maintain Its Avascularity?”
- •General Mechanisms
- •Corneal Hemangiogenesis After Low-Risk Keratoplasty
- •Corneal Hemangiogenesis After High-Risk Keratoplasty
- •Corneal Lymphangiogenesis: Essential for Corneal Graft Rejection
- •Corneal Lymphangiogenesis in Dry Eye
- •Imaging of Corneal Lymphatic Vessels
- •Novel Anti(lymph)Angiogenic Treatment Options at the Cornea
- •Current Treatment Options for Immature Corneal (Blood and Lymphatic) Vessels
- •Steroids
- •Anti-VEGFs (Bevazicumab, Ranibuzumab, Pegaptanib, VEGF Trap)
- •Anti-IRS 1-Strategies (Antisense Oligonucleotides Against IRS 1)
- •Treatment Options for Mature Corneal Vessels
- •Unmet Needs and Future Directions
- •References
- •Core Messages
- •Introduction
- •Retrieval of Donor Tissue
- •Technical Aspects
- •Microbiological Aspects
- •Tissue Evaluation Aspects
- •Corneal Storage
- •Moist Chamber Storage of the Donor Eye
- •Technical Aspects
- •Storage Period
- •Microbiological Safety
- •Tissue Evaluation
- •Hypothermic Storage of the Corneoscleral Button
- •Technical Aspects
- •Storage Period
- •Microbiological Safety
- •Tissue Evaluation
- •Organ Culture (Normothermic Storage) of the Corneoscleral Button
- •Technical Aspects
- •Storage Period
- •Microbiological Safety
- •Tissue Evaluation
- •Other Aspects
- •Pre-cutting of Corneal Tissue for Endothelial Keratoplasty (EK)
- •Microkeratome Cutting
- •Femtosecond Laser Cutting
- •Stripping of Descemet’s Membrane with Endothelium
- •Donor Considerations for EK
- •References
- •7: Infant Keratoplasty
- •Core Messages
- •Introduction
- •Indications for Surgery
- •Visual Outcome
- •Patient Selection
- •Patient Assessment
- •Ancillary Testing
- •Donor Tissue
- •Intraoperative Considerations
- •Concurrent Surgical Procedures
- •Postoperative Considerations
- •Suture Management
- •Optical Correction and Amblyopia Therapy
- •Postoperative Complications
- •Glaucoma
- •Graft Rejection
- •Graft Failure
- •Alternatives to Penetrating Keratoplasty
- •Conclusion
- •References
- •Index
92 |
E. Pels and G. Pollock |
|
|
•Different recovery procedures, storage techniques, and in more recent years, tissue processing techniques, have been introduced and each have their own benefits and risks in regard to their technical, microbiological and tissue evaluation aspects.
•Eye bank preparation of donor tissue for lamellar endothelial keratoplasty procedures is evolving rapidly but presents unique challenges to the eye bank, especially in regard to handling and iatrogenic damage during processing.
Introduction
The foundations of eye banking and corneal preservation were laid by Filatov in 1937 with the recognition that donor tissue for corneal transplants could be recovered post-mortem [1]. For many years, the ophthalmic surgeon was in direct control of the process, often being directly responsible for both procurement of donor tissue and the transplant surgery itself. However, over the past few decades, the responsibility for the provision of a viable, disease-free donor cornea has been entrusted to the eye bank, and the ophthalmic surgeons now have to rely on these services as an important aspect of their surgery and treatment.
The first eye bank was perhaps the Eye Bank for Sight Restoration in New York, founded in 1944. At this time, eye banks functioned as collection centres and simple storage facilities, holding whole globes in moist pot storage prior to corneal transplantation, which was usually undertaken within 24 h of donor eye retrieval. Eye banking practices expanded during the 1970s with the development of corneoscleral storage solutions [2] which allowed, for several days, storage and the refinement of corneal evaluation procedures to determine the suitability and likely efficacy of a cornea for a particular transplant procedure. Such activity helped support the rapid growth of corneal transplantation over the same period which was being driven by advances in instrumentation, surgical microscopy and suture development. Accompanying such growth was the appreciation that corneal transplantation could potentially transmit a number of diseases from donor to recipient, and eye banks became increasingly responsible for donor screening for such diseases [3]. Many of the standards to assist in these practices were initially developed by the Eye Bank Association of America (EBAA, www.restoresight.org) who produced their first set of Medical Standards in 1980. These standards are maintained and updated by rigorous and regular review processes. Other Eye Banks and Eye Banking associations, such as the European Eye Bank Association (EEBA, www.europeaneyebanks. com) and the Eye Bank Association of Australian and New Zealand (EBAANZ, www.ebaanz.org) have also developed their own set of Standards using those of the EBAA as their basis and cover areas such as donor selection and testing, personnel and training, facilities and equipment, documentation, procurement and corneal preservation.
